Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis

被引：5
作者：
Brannigan, Jamie [1 ]
Jones, Joanne L. [2 ]
Stacpoole, Sybil R. L. [1 ,2 ,3 ]
机构：
[1] Univ Cambridge, Jesus Coll, Cambridge CB2 1TN, England
[2] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Neurol, Cambridge, England
[3] North West Anglia NHS Fdn Trust, Peterborough City Hosp, Dept Neurol, Peterborough, Cambs, England
来源：
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION | 2020年 / 7卷 / 05期
基金：
英国惠康基金;
关键词：
D O I：
10.1212/NXI.0000000000000799
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
A 39-year-old right-handed agricultural service engineer developed rapidly evolving severe relapsing-remitting multiple sclerosis (MS). MRI showed multiple T2 hyperintensities throughout his neuroaxis (figure, A). Several lesions showed restricted diffusion, and 2 enhanced. He received steroids for each relapse, making a full recovery (Expanded Disability Status Score [EDSS] 0).
引用
收藏
页数：3
相关论文
共 4 条
  • [1] Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy
    Haghikia, Aiden
    Dendrou, Calliope A.
    Schneider, Ruth
    Grueter, Thomas
    Postert, Thomas
    Matzke, Mike
    Stephanik, Heike
    Fugger, Lars
    Gold, Ralf
    [J]. LANCET NEUROLOGY, 2017, 16 (02) : 104 - 106
  • [2] Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
    Jones, Joanne L.
    Thompson, Sara A. J.
    Loh, Priscilla
    Davies, Jessica L.
    Tuohy, Orla C.
    Curry, Allison J.
    Azzopardi, Laura
    Hill-Cawthorne, Grant
    Fahey, Michael T.
    Compston, Alastair
    Coles, Alasdair J.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (50) : 20200 - 20205
  • [3] Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis
    Wehrum, Thomas
    Beume, Lena-Alexandra
    Stich, Oliver
    Mader, Irina
    Maeurer, Mathias
    Czaplinski, Adam
    Weiller, Cornelius
    Rauer, Sebastian
    [J]. NEUROLOGY, 2018, 90 (07) : E601 - E605
  • [4] An observational study of alemtuzumab following fingolimod for multiple sclerosis
    Willis, Mark
    Pearson, Owen
    Illes, Zsolt
    Sejbaek, Tobias
    Nielsen, Christian
    Duddy, Martin
    Petheram, Kate
    van Munster, Caspar
    Killestein, Joep
    Malmestrom, Clas
    Tallantyre, Emma
    Robertson, Neil
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2017, 4 (02):
1